Why the Glucagon Receptor Matters: The Third Component of Triple Agonism

The Overlooked Hormone

For decades, glucagon was seen mainly through the lens of diabetes: the hormone that raises blood glucose and works against insulin. In clinical medicine, glucagon is used as an emergency treatment for severe hypoglycemia. Deliberately activating the glucagon receptor as a treatment has long seemed backwards.

Newer evidence shows that glucagon’s metabolic effects go well beyond blood sugar. Glucagon receptor agonism increases energy expenditure, promotes fat burning in the liver, lowers liver fat and may boost heat production (thermogenesis). That makes the glucagon receptor an attractive target for obesity and metabolic liver disease, as long as its glucose-raising effect can be offset by activating the GLP-1 receptor at the same time.

That is exactly what retatrutide is designed to do.

Glucagon and Energy Expenditure

Most approved and investigational obesity treatments work mainly on the “calories in” side of energy balance. GLP-1 receptor agonists suppress appetite in the brain, so people eat less. GIP receptor agonism adds to this through related pathways. The result is meaningful weight loss, but only one side of the equation is addressed.

Glucagon receptor activation adds the “calories out” side. Preclinical studies have consistently shown that glucagon raises resting energy expenditure. The mechanisms include:

• Increased hepatic energy consumption: Glucagon stimulates processes in the liver, including gluconeogenesis and fatty acid oxidation, that use energy.
• Activation of brown adipose tissue: Glucagon signaling promotes heat production in brown fat, turning stored energy into heat rather than ATP.
• Enhanced mitochondrial activity: Glucagon receptor activation increases mitochondrial uncoupling and oxidative metabolism in several tissues.

The net effect is that the body burns more energy at rest. Combined with eating less because of GLP-1 and GIP receptor activation, this two-sided effect on energy balance may explain why retatrutide’s Phase 2 weight loss was greater than that of dual agonists.

Glucagon and Hepatic Fat Metabolism

Glucagon receptor agonism may matter most clinically for its effect on liver fat. Glucagon directly promotes fatty acid oxidation in the liver, the process by which the liver breaks down stored fat for energy. This is separate from the indirect drop in liver fat that comes with weight loss alone.

In the Phase 2 retatrutide trial, participants had an approximately 82% relative reduction in liver fat, measured by MRI-PDFF. That is far more than the weight loss alone would predict. For comparison, GLP-1 receptor agonists usually cut liver fat by 30-40%, mostly as a result of weight loss and better insulin sensitivity.

The extra liver fat clearance with retatrutide most plausibly comes from the glucagon receptor component, which directly speeds up how the liver gets rid of fat. Preclinical studies support this, showing that glucagon receptor agonism reduces fatty liver regardless of changes in body weight.

The Glucose Paradox: How GLP-1 Solves It

The long-standing worry with glucagon receptor agonism has been high blood sugar. Glucagon makes the liver release glucose, which on its own would worsen blood sugar control. That is why pure glucagon receptor agonists have not been developed as metabolic drugs.

Retatrutide deals with this through its GLP-1 receptor activity. GLP-1 receptor agonism strongly stimulates insulin release, suppresses unneeded glucagon release from alpha cells and slows stomach emptying, all of which counter the glucose-raising effect of glucagon receptor activation. In the Phase 2 trials, blood sugar measures improved in every dose group, confirming that the GLP-1 component effectively cancels out the high blood sugar risk of the glucagon component.

Getting this balance right is a key achievement of the triple agonist design. The molecule captures glucagon’s metabolic benefits without its main clinical drawback.

Thermogenesis and Beyond

Beyond energy expenditure and liver fat, glucagon receptor agonism may help metabolic health in other ways that are still being studied:

• Amino acid metabolism: Glucagon plays a central role in breaking down amino acids and making urea, and its effects reach protein turnover pathways that may influence body composition.
• Cardiovascular effects: Glucagon acts directly on the heart, raising heart rate and the force of contraction. The long-term effects on the heart of steady, low-level glucagon receptor stimulation are being studied in ongoing trials.
• Lipid metabolism: Beyond the liver, glucagon affects blood lipid levels and the breakdown of fat in fat tissue, which may help improve triglycerides and other lipid measures.

Why This Distinction Matters Clinically

The glucagon receptor component is what sets retatrutide apart from dual GIP/GLP-1 agonists like tirzepatide. Tirzepatide has shown impressive efficacy, but it works mainly through appetite suppression and better insulin sensitivity. Retatrutide adds something different, higher energy expenditure and direct clearing of liver fat, which may mean more weight loss and much greater liver fat reduction.

For patients with MASLD, this difference could be transformative. Metabolic liver disease affects about 25% of adults worldwide, and effective drugs are still badly needed. A drug that targets liver fat directly through glucagon receptor agonism, rather than relying only on weight loss, could be a more effective treatment.

The glucagon receptor, once seen as a liability, may turn out to be the most valuable part of the triple agonist design.